3.1. Data Collection
Following an applied, descriptive-correlational study design, this study was conducted on all patients with psoriasis referred to the rheumatology clinic of Golestan Hospital in Ahvaz in the first half of 1398. After obtaining approval from the ethics committee of Ahwaz Jundishapur University of Medical Sciences (AJUMS) (No IR.JUMS.REC.1397.936), the researcher referred to the study site (the rheumatology clinic of Golestan Hospital in Ahvaz). A total of 104 patients with psoriasis were identified and all of them were included in the study using a census sampling method. The inclusion criteria were a definitive diagnosis of psoriasis by a dermatologist and willingness to participate in the study. The exclusion criteria included having a history of neurological disease, suffering from severe cognitive impairment, using psychiatric medications during the study, addiction to any drugs; patients with uncontrolled chronic diseases such as diabetes, hypertension, and heart disease; and unwillingness to participate.
3.2. Diagnostic Evaluations
After obtaining written informed consent from all participants, they were provided with the standardized Symptom Checklist-90 (SCL90) questionnaire [Derogatis et al. (1973)]. The questionnaire is revised based on clinical experiences and psychometric analyses (in 1976). If they requested further information, the researcher provided them all the necessary information about the objectives of the study. Of 114 questionnaires distributed, 104 responded for a response rate of 91%.
A study by Mirzaei (1980) has standardized the SCL90 in Iran. Derogotis (1976) evaluated the internal consistency of this test. The highest and lowest correlation coefficients were associated with depression (0.95) and psychoticism (0.77), respectively. To evaluate the reliability of the questionnaire, a pilot study was conducted on 94 patients with mental health problems using the test-retest method. The correlation coefficients ranged from 0.78 to 0.90 after one week of administration. Regarding the validity of the test, the highest and lowest reported correlations are 0.73 and 0.36 for phobic anxiety, respectively.
Test scoring and interpretation were based on three indices of global severity index (GSI), positive symptom distress index (PSDI), and positive symptom total (PST). On average, administering the test lasted about 12 to15 minutes. The SCL90 intends to evaluate the individual’s conditions since the last week. It contains 9 different dimensions as follows: (1) somatization (SOM), the individual perceives the pathological function of his/her body; (2) obsessive-compulsive (O-S), the individual focuses on thoughts, impulses, and actions that are unintentional; (3) interpersonal sensitivity (INS), the individual experiences feelings of inadequacy, inferiority, and discomfort when communicating with others; (4) depression (DEP), experiencing helplessness and hopelessness, a loss of interest in pleasurable things in life, and a dysphoric mood; (5) anxiety (ANX), the individual experiences a great deal of anxiety; (6) hostility (HOS), the individual has thoughts, actions, and feelings that characterize the state of anger; (7) phobic anxiety (PHO), the individual experiences strong, irrational fear of a particular stimulus; (8) paranoid ideation (PAR), the individual is pessimistic about others and feels suspicious of others; (9) psychoticism (PSY), the individual has psychotic symptoms (with low to severe intensity).
Besides, to prevent subjects' awareness about the nature of the test, 7 items are embedded in a scattered manner, which are scored similarly to the rest of the items. Regarding the deletion of 7 scattered questions, the achievable score is between 0 and 332, and the mental health status of each individual. Based on the obtained score, participants can be categorized into groups of no psychiatric disorder (score of 0 to 84), mild psychiatric disorder (85 to 168), moderate psychiatric disorder (169 to 253), and severe psychiatric disorder (254 to 332). Regarding the prevalence of psychiatric symptoms, a score of 0 to 1 represents no disorder, 1.01 to 2 mild disorder, 2.01 to 3 moderate disorder, and 3.01 to 4 severe disorder.
This 90-item questionnaire is scored on a five-point Likert scale, ranging from zero ("not at all" to 4 ("extremely") (1 = a little bit, 2 = moderately, and 3 = quite a bit). In scoring, the first step is to provide the key to calculating the total score on each dimension. To do this, ten keys are prepared to calculate the scores on the nine symptom dimensions and other items. In the second step, the total score of each dimension should be transferred to the table used for recording the subjects’ scores in an answer sheet. The total score is the sum of scores obtained for each dimension. In the third step, to obtain the mean score of the symptoms in each dimension, the total score obtained of each subject in all dimensions of the questionnaire (except for additional items) should be divided by the number of items in each dimension. Then, the mean score of the symptoms in each dimension should be specified in the summary table designed for displaying the information of each subject. Afterward, the global severity index (GSI) can be calculated, meaning that the total score obtained for each subject in the nine symptom dimensions and the additional items should be summed up and then be divided by 90 (the total number of items) to obtain the GSI. Then, the number of items in which the subject has obtained a zero score should be subtracted from the total number of items (i.e. 90) to calculate the PST. In the next step, the total GSI score should be divided by the total PSI score to obtain the PSDI score.